



**Chelsea and Westminster Hospital NHS Foundation Trust  
Trust Medicines Group**

**Summary of Main Points from the Meeting held on Monday 12<sup>th</sup> November 2018**

**2. Minutes and Summary Notes from last meeting**

The Minutes and Summary notes from the 8<sup>th</sup> October 2018 Medicines Group meeting were approved and will be circulated.

**3. Matters Arising**

The Group noted the matters arising from the previous meeting.

**4. Business to be transacted by the Medicines Group**

**4.1 Formulary Applications**

***Full Applications***

- **Symtuza (Darunavir (as ethanolate) 800mg, Cobicistat 150mg, Emtricitabine 200mg and Tenofovir alafenamide (as fumarate) 10mg**

New HIV combination Anti-retroviral. Approved for addition to the formulary by HIV & GUM Sub-Group. NHS England have updated and published Cobicistat Policy accordingly.

**Outcome: Noted**

***Ex-panel***

- Nil

***Removals***

- Nil

***NICE Approved drug applications***

- Nil

***Pharmacoeconomic Board requests***

- **Baricitinib for Rheumatoid Arthritis**

Approved by the Pharmacoeconomic Board on 02/10/18

For noting by the Group.

**Outcome: Noted**

- **Rituximab for Opsoclonus Myoclonus**

Approved by the Pharmacoeconomic Board on 19/10/18

For noting by the Group.

**Outcome: Noted**

**4.2 Trust Medicines Policy**

- **TMP - Section 4: Storage of medicines**

Updated to include new section 4.9 - Setting up new medicine refrigerators and freezers in clinic areas.

**Outcome: Approved**

- **TMP - Section 8: Administration of medicines**

Updated to include documentation of the date stock bottles of liquid medicines are opened and the assigned expiry date using the expiry date stickers supplied by Pharmacy to wards/departments.

**Outcome: Approved**

- **TMP - Section 5: Handling and transport of medicines**



## Chelsea and Westminster Hospital NHS Foundation Trust Trust Medicines Group

Updated to include:

- Hospital volunteers collecting medicines from Pharmacy
- New section relating to the use of pneumatic air tube systems for transporting of medicines

**Outcome: Approved**

- **TMP - Section 34: Supply and administration of medicines by Non-registered Healthcare professionals**

Updated to include:

- A new clinical scenario approved by TMG: Administration of cardiac medications during Stress and Contrast Echocardiography by Cardiac Physiologists.
- Supply of medicines as well as the administration of medicines.

Change in title to cover supply and administration of medicines and also staff grouped as "Non-registered Healthcare professionals".

**Outcome: Approved**

- **Administration of cardiac medications within EMIC by Cardiology Physicians**

New policy for the administration of cardiac medications by non-registered Cardiac Physicians.

Enclosures included:

- Policy
- Risk assessment

**Outcome: Approved with some amendments to be made to the policy**

- **Updates to Neonatal/Paediatric IV Administration Guide**

Updates to IV Neonatal/Paediatric IV Administration Guide following a review against current SPCs

It was also noted that both the Adult and Paediatric IV Guides are now uploaded in the Medicines Policy (and related documents) Trust intranet Mini-site giving Pharmacy full control to upload updated versions as they get approved.

**Decision: Approved**

### 4.3 Medicines Optimisation

- **Compliance to NICE Guidance - MPG2: Patient Group Direction**

Report that summarises the Trust compliance status with NICE Guidance MPG2: Patient Group Direction and resulting action plan to gain full compliance.

Enclosures included:

- NICE Guidance
- Trust Compliance Status Report (Including Action Plan)

The action plan centres around two main areas of improvement:

- Uploading of all PGDs across the Trust on the hospital intranet web site so they are visible to staff who use them
- Audit of all Trust PGDs (There are approximately 60 in total)

**Outcome: Approved**

- **Allergy migration on Cerner**

The options for Allergy Migration on Cerner EPR was presented.

**Outcome: Noted**

### 4.4 NICE Technical Appraisals and Guidance

#### a) **NICE Technical Appraisals**

**3 Appraisals published in October 2018**

**TA542 - Cabozantinib for untreated advanced renal cell carcinoma**

**Formulary status / Action**

**Nil - Currently included on the formulary for advanced renal cell carcinoma.**

**TA543 - Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs**



**Chelsea and Westminster Hospital NHS Foundation Trust  
Trust Medicines Group**

**Formulary status / Action**

Currently included on the formulary for moderate to severe Rheumatoid Arthritis.

Numbers likely to treat at CWH site for this indication: 10 patients per year.

Numbers likely to treat at WMUH site for this indication: 5 patients per year.

**TA544 – Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma**

**Formulary status / Action**

Currently included on the formulary for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.

To confirm the number of patients likely to treat for this indication.

**b) NICE Highly Specialised Technologies**

**0 Highly Specialised Technologies published in October 2018**

**4.5 IVIG requests**

**CWH Site**

- IVIG issues for October 2018 - CW site
- There were 13 IVIG issues in September 2018, with 7 new requests:

**WMUH Site**

- IVIG issues for October 2018 - WMUH site
- There were 15 IVIG issues in September 2018, with 5 new requests

**4.6 Items for noting**

• **Letter regarding the prescribing of Dymista<sup>®</sup> at WMUH**

Letter drafted to ENT consultants at WMUH regarding the prescribing of Dymista<sup>®</sup> at WMUH.

**Decision: Noted**

• **Trust Patient Safety Group Report - October 2018**

Trust Patient Safety Group report for October 2018

**Decision: Noted**

• **Medication Safety Bulletin - Paracetamol Dosing in Paediatrics**

Medication Safety Bulletin relating to paracetamol dosing in paediatrics

**Decision: Noted**

• **Letter from Bayer regarding Bevacizumab**

Letter from Bayer relating to a court case between Bayer and some Northern CCGs over their policy to use compounded Bevacizumab in favour of licensed Eylea or Lucentis for reasons of cost.

**Decision: Noted**

• **CAS Alert - Adrenaline Auto-Injectors**

CAS Alert regarding shortage of Adrenaline Auto-injectors and relating memo.

**Decision: Noted**

• **MHRA Drug Safety Update - October 2018**

MHRA update for September 2018

**Decision: Noted**

**4.7 Meeting minutes for noting**

• **Medication Safety Group Meeting - September 2018**

Minutes from Medication Safety Group Meeting - September 2018



**Chelsea and Westminster Hospital NHS Foundation Trust  
Trust Medicines Group**

**Decision: Noted**

- **HIV/GUM Directorate - Medicines Sub-Group Meeting - September 2018**

Minutes from HIV/GUM Directorate - Medicines Sub-Group Meeting -September 2018

**Decision: Noted**

- **Antimicrobial Steering Group Meeting - October 2018**

Minutes from Antimicrobial Steering Group Meeting - October 2018

**Decision: Noted**

**4.8 Additional papers to go to Trust Patient Safety Group**

Nil

**5. Any other business**

Nil

**6. Date of next meeting**

**Date: Monday 10<sup>th</sup> December 2018**

**Time: 8am-9am**

**Location: Board Room (CWH Site) and Meeting Room A (WMUH Site via video conferencing)**

**Closing date: 16<sup>th</sup> November 2018**